Theravance Biopharma Inc. (NASDAQ:TBPH)’s share price hit a new 52-week high on Friday . The company traded as high as $25.16 and last traded at $25.14, with a volume of 123,571 shares traded. The stock had previously closed at $24.37.

A number of equities analysts have recently weighed in on TBPH shares. Zacks Investment Research lowered Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, April 19th. Bank of America Corp. lowered Theravance Biopharma from a “buy” rating to a “neutral” rating in a research report on Thursday, May 5th. Leerink Swann started coverage on Theravance Biopharma in a research report on Thursday, May 12th. They set an “outperform” rating and a $26.00 target price on the stock. Finally, Guggenheim started coverage on Theravance Biopharma in a research report on Monday, June 20th. They set a “buy” rating and a $30.00 target price on the stock. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $24.75.

The company’s market capitalization is $1.21 billion. The stock has a 50 day moving average of $22.94 and a 200 day moving average of $19.72.

Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings results on Monday, May 9th. The biopharmaceutical company reported ($1.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.96) by $0.14. The company earned $18.40 million during the quarter, compared to analyst estimates of $18.69 million. Analysts forecast that Theravance Biopharma Inc. will post ($4.24) EPS for the current fiscal year.

A hedge fund recently raised its stake in Theravance Biopharma stock. OppenheimerFunds Inc. raised its position in Theravance Biopharma Inc. (NASDAQ:TBPH) by 1.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,103,485 shares of the biopharmaceutical company’s stock after buying an additional 12,120 shares during the period. OppenheimerFunds Inc. owned 2.92% of Theravance Biopharma worth $18,086,000 as of its most recent filing with the SEC.

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines that make a difference in the lives of patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.